Brie Carter

Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its proprietary TALEN® gene-editing platform to develop next-generation immunotherapies, announced its financial and operational results for the fiscal year ended December 31, 2025.

A new tax reporting rule in the United Kingdom now requires crypto platforms to submit detailed user data to HM Revenue & Customs and to authorities in more than 70 countries.

Qantas (ASX:QAN) will review airfare pricing fortnightly and consolidate flights as soaring fuel costs and Middle East conflict volatility impact international operations.

United States Antimony (NYSE:UAMY) announced its financial results for the fiscal year ended December 31, 2025, reporting a period of exponential top-line growth driven by the tightening global supply of critical minerals.

The Cato Corporation (NYSE:CATO) announced its financial results for the fourth quarter and full fiscal year ended January 31, 2026, showcasing a year of operational refinement and narrowed losses.

Almonty Industries (ASX:AII) reported annual revenue of CAD$32.5 million for 2025, up from CAD$28.8 million in 2024.

Star Minerals (ASX:SMS) said all conditions precedent have been satisfied for the divestment of its West Bryah Copper-Gold Project to Catalyst Metals (ASX:CYL).

Theravance Biopharma (NASDAQ:TBPH) on Thursday reported financial results for the fourth quarter and full year ended December 31, 2025, revealing a year of significant financial recovery tempered by a major strategic pivot.

Movado Group (NYSE:MOV) today announced its financial results for the fourth quarter and full fiscal year ended January 31, 2026, highlighting a period of robust operational leverage and steady top-line growth.

Accenture (NYSE:ACN) reported solid financial results for the second quarter of fiscal 2026, ended February 28, 2026, characterized by steady revenue growth and robust demand for its strategic consulting and technology services.